Economy

Trump's tariff policy
Trump promises no or "much lower" taxes

Donald Trump's "tariff dividends" to the people will begin next year and according to the president, it is just the beginning. Over the next two to four years, dividends will increase and the national debt will decrease due to the thousands of billions of dollars in tariffs, Trump says during a cabinet meeting.

- And in the not too distant future, I think you won't even have to pay income tax, the president says according to Real Clear Politics.

And if the tax is not abolished completely, it will be "much lower than it is now," Trump adds.

Sanctions
EU agrees: Will phase out Russian gas by 2027

The European Council has reached an agreement with the European Parliament to phase out Russian gas imports by 2027. This is stated in a press release.

- A historic day for our union. We are turning a page and doing it for good. This is the beginning of Europe's full independence from Russian energy, says EU Commission President Ursula von der Leyen at a press conference in Brussels.

The agreement involves gradual restrictions on both liquid and pipeline gas from Russia, with a complete ban in the fall of 2027.

In October, Russia accounted for 12 percent of the EU's gas imports.

Volvo Cars' future
Volvo sales fell: "Highlighting the challenges"

Volvo Cars' global car sales fell by 10 percent in November, the company wrote in a press release.

- November's sales figures highlight the ongoing structural and transformative challenges that affect both Volvo Cars and the industry at large, says Erik Severinson, the company's commercial director.

New obesity drugs
Novo applies for state support after WHO's statement

Novo Nordisk has applied for subsidies from the Danish state twice and been rejected. But after the World Health Organization (WHO) made a statement on Monday, Novo Nordisk is now preparing a third application, Børsen reports.

On Monday, the WHO recommended for the first time that severely obese people worldwide should be treated with medication and that states should ensure “equal access” to “adequate treatment.”

This would be a win for Novo, which has already applied for general funding for Wegovy in Denmark, but has been rejected twice by the Danish Medicines Agency.